Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
QNRX
Upturn stock ratingUpturn stock rating

Quoin Pharmaceuticals Ltd DRC (QNRX)

Upturn stock ratingUpturn stock rating
$6
Last Close (24-hour delay)
upturn advisory
PASS
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

04/22/2025: QNRX (1-star) is currently NOT-A-BUY. Pass it for now.

Upturn Star Rating

rating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

Number of Analysts

rating

2 Analysts rated it

Very few follow this stock; limited insights, higher-risk early investing.

1 Year Target Price $150

1 Year Target Price $150

Analysts Price Target For last 52 week
$150Target price
Low$5.01
Current$6
high$37.8

Analysis of Past Performance

Type Stock
Historic Profit -95.2%
Avg. Invested days 17
Today’s Advisory PASS
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 1.0
Stock Returns Performance Upturn Returns Performance 1.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 04/22/2025

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 5.45M USD
Price to earnings Ratio -
1Y Target Price 150
Price to earnings Ratio -
1Y Target Price 150
Volume (30-day avg) 2
Beta 1.78
52 Weeks Range 5.01 - 37.80
Updated Date 07/1/2025
52 Weeks Range 5.01 - 37.80
Updated Date 07/1/2025
Dividends yield (FY) -
Basic EPS (TTM) -34.47

Earnings Date

Report Date -
When -
Estimate -
Actual -

Profitability

Profit Margin -
Operating Margin (TTM) -

Management Effectiveness

Return on Assets (TTM) -47.4%
Return on Equity (TTM) -138.82%

Valuation

Trailing PE -
Forward PE -
Enterprise Value -6123943
Price to Sales(TTM) -
Enterprise Value -6123943
Price to Sales(TTM) -
Enterprise Value to Revenue -
Enterprise Value to EBITDA -0.42
Shares Outstanding 588167
Shares Floating 18047816
Shares Outstanding 588167
Shares Floating 18047816
Percent Insiders 7.08
Percent Institutions 7.2

Analyst Ratings

Rating 1
Target Price 150
Buy 1
Strong Buy 1
Buy 1
Strong Buy 1
Hold -
Sell -
Strong Sell -
Strong Sell -

ai summary icon Upturn AI SWOT

Quoin Pharmaceuticals Ltd DRC

stock logo

Company Overview

overview logo History and Background

Quoin Pharmaceuticals, founded in 2017, is a specialty pharmaceutical company focused on rare and orphan diseases. It licenses and develops products to address unmet medical needs, particularly in dermatology.

business area logo Core Business Areas

  • Dermatology: Focuses on developing and commercializing products for rare skin diseases.

leadership logo Leadership and Structure

Details on the leadership team and organizational structure were not available in my knowledge cut-off

Top Products and Market Share

overview logo Key Offerings

  • QRX003: Lead product candidate is being developed for Netherton Syndrome. Currently in clinical development. No market share or revenue information available as it's not yet approved. Competitors depend on which symptoms QRX003 effectively alleviates, but could include companies that make emollients.

Market Dynamics

industry overview logo Industry Overview

The rare disease market is growing, driven by increased awareness, regulatory incentives, and advancements in diagnostics. Dermatology is a lucrative segment within pharmaceuticals.

Positioning

Quoin is positioned as a developer of niche treatments for rare dermatological conditions. Its competitive advantage depends on the successful development and commercialization of its pipeline.

Total Addressable Market (TAM)

The TAM depends on the specific rare diseases Quoin targets. Netherton Syndrome affects a relatively small population, but the pricing of orphan drugs can result in significant revenue potential if a product is approved.

Upturn SWOT Analysis

Strengths

  • Focus on rare diseases
  • Potential for orphan drug designation and market exclusivity
  • Experienced management team

Weaknesses

  • Reliance on a limited number of pipeline products
  • High risk associated with drug development
  • Need for significant capital to fund research and development

Opportunities

  • Expansion of pipeline through licensing or acquisitions
  • Strategic partnerships with larger pharmaceutical companies
  • Increased awareness and diagnosis of rare diseases

Threats

  • Clinical trial failures
  • Regulatory hurdles
  • Competition from other companies developing treatments for rare diseases
  • Manufacturing or supply chain issues

Competitors and Market Share

competitor logo Key Competitors

  • This information is not available without comprehensive market research. Companies competing in similar therapeutic areas may exist.

Competitive Landscape

Quoin's advantage depends on the uniqueness and efficacy of its products. They will have to navigate complex regulatory and competitive factors.

Growth Trajectory and Initiatives

Historical Growth: The company's historical growth is tied to the progression of its pipeline.

Future Projections: Future growth depends on successful clinical trials and regulatory approvals.

Recent Initiatives: Recent initiatives likely include clinical trial activities and potential partnership discussions.

Summary

Quoin Pharmaceuticals is a development-stage pharmaceutical company focused on rare diseases, primarily in dermatology. Its success hinges on the successful development and commercialization of its lead product candidates. Clinical trial outcomes, regulatory approvals, and securing necessary financing are critical factors for its future growth. Due to its early stage, the company is speculative.

Peer Comparison

Sources and Disclaimers

Data Sources:

  • Company website
  • SEC filings (where available)
  • Publicly available news and information

Disclaimers:

The information provided is for informational purposes only and should not be considered investment advice. Please consult with a financial professional before making any investment decisions.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.

About Quoin Pharmaceuticals Ltd DRC

Exchange NASDAQ
Headquaters Ashburn, VA, United States
IPO Launch date 2016-07-29
Co-Founder, CEO & Chairman Dr. Michael Myers Ph.D.
Sector Healthcare
Industry Biotechnology
Full time employees 3
Full time employees 3

Quoin Pharmaceuticals, Ltd., a late stage specialty pharmaceutical company, focuses on the development and commercialization of therapeutic products for rare and orphan diseases in the United States. The company's lead product is QRX003, a topical lotion to treat Netherton Syndrome (NS). It also developing QRX004 for the treatment of recessive dystrophic epidermolysis bullosa; QRX007 to treat Netherton Syndrome; and QRX008 for the treatment of scleroderma. It has a research agreement with Queensland University of Technology; a license agreement with Skinvisible Inc.; consulting agreements with Axella Research LLC; and a Master Service Agreement with Therapeutics Inc. Quoin Pharmaceuticals, Ltd. was founded in 2018 and is based in Ashburn, Virginia. Quoin Pharmaceuticals, Ltd. is a subsidiary of Skinvisible, Inc.